Repatha, a PCSK9 inhibitor, lowers cholesterol well, especially for those intolerant to statins, but its absolute risk ...
Amgen CEO Robert Bradway has declared 2026 a “springboard year” for the California big biotech, in which the growth of its ...
Investor's Business Daily on MSN
Amgen's numbers are out: It gets to keep its cholesterol crown — for now
Amgen widely beat the Street's first-quarter expectations late Thursday, slightly ticking its 2026 guidance higher.
Amgen Inc (AMGN) reports a robust 4% growth in product sales, driven by key growth drivers, while navigating patent expirations and increased competition.
I’m a 75-year-old woman who’s in very good health. Since my early 50s, I’ve had issues with my cholesterol. My ...
Amgen Inc () has held its Q1 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks. Unlock hedge fund-level data and powerful investing tools for smar ...
I’m a 75-year-old woman who’s in very good health. Since my early 50s, I’ve had issues with my cholesterol. My doctor has put ...
Most Medicare drug plans cover Repatha (evolocumab). This includes stand-alone Part D prescription drug plans and Medicare Advantage plans that include prescription drug coverage. Doctors prescribe ...
Amgen has a new tool to employ in its battle with Sanofi and Regeneron for PCSK9 market dominance. The drugmaker said today that the FDA has approved a new hands-free injector for a once-monthly dose ...
Repatha is a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. Amgen has announced a price reduction for Repatha (evolocumab), bringing the list price of the therapy to $5,850 per year, ...
It’s not known whether Repatha (evolocumab) is safe to use while pregnant or breastfeeding. Certain factors may determine whether you should use the drug during this time. It’s not known whether it’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results